跳至主要内容
临床试验/NCT06135727
NCT06135727终止不适用

Data Collection for Development of Topcon Health Score

Topcon Corporation1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2023年11月7日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
26
试验地点
1
主要终点
RNFL and GCL thickness

研究概览

简要总结

The objective of this study is to collect data for the development and validation a screening process using aggregate data.

In this study, data collection will encompass both retrospective and prospective approaches across multiple sites in the United States.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects 22 years of age or older on the date of data collection (retrospective) or informed consent (prospective).
  • For prospective data collection or missing retrospective data collection, subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent.
  • BCVA 20/40 or better (each eye).
  • Normal eyes to have normal ocular examination in both eyes
  • Normal eyes to have IOP ≤ 21 mmHg in both eyes
  • Pathology eyes to have clinical diagnosis of mild or moderate glaucoma in at least one eye

排除标准

  • For prospective or missing retrospective data collection, subjects unable to tolerate ophthalmic testing.
  • Concomitant diseases known to affect the visual field: history of leukemia, dementia, Parkinson's disease, Alzheimer's disease, stroke, or autoimmune diseases.
  • History of intraocular surgery (uncomplicated cataract or glaucoma surgeries are accepted)
  • Ocular findings or history of co-morbidities, including, but not limited to: uveitis, non-glaucomatous optic neuropathy, trauma, retinal detachment, vein or artery occlusions, wet age-related macular degeneration, geographic atrophy, proliferative diabetic retinopathy, vitreous hemorrhage, severe cataract, severe non-proliferative diabetic retinopathy. Controlled diabetes and hypertension participants can be included.
  • Unreliable VF testing and/or poor-quality OCT scans.
  • Poor fixation.
  • Pathology eyes with severe glaucoma
  • Pathology eyes with glaucoma suspect diagnosis
  • Pathology eyes with Ocular Hypertensive diagnosis

结局指标

主要结局

RNFL and GCL thickness

时间窗: 1 day

Using Maestro2 OCT

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Screening Protocol | 临床试验